000 03620naa a22004697i 4500
001 UMUN-OA-20261005-MLS-040
003 local
005 20261005174904.0
006 m o d
007 cr||||||||||||
008 261005s2023 xx o u000 0 eng d
024 7 _a10.1038/s41392-023-01521-5
_2doi
035 _a(local)EuropePMC:PMC10435569
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aLu Tang
_eauthor.
245 1 0 _aImmunotherapy in hematologic malignancies: achievements, challenges and future prospects. /
_cLu Tang; Zhongpei Huang; Heng Mei [and others].
264 1 _a[Place of publication not identified] :
_bNature Publishing Group,
_c2023.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aThe immune-cell origin of hematologic malignancies provides a unique avenue for the understanding of both the mechanisms of immune responsiveness and immune escape, which has accelerated the progress of immunotherapy. Several categories of immunotherapies have been developed and are being further evaluated in clinical trials for the treatment of blood cancers, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies. These immunotherapies have shown the potential to induce long-term remission in refractory or relapsed patients and have led to a paradigm shift in cancer treatment with great clinical success. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. To provide clinicians with timely information on these revolutionary therapeutic approaches, the comprehensive review provides historical perspectives on the applications and clinical considerations of the immunotherapy. Here, we first outline the recent advances that have been made in the understanding of the various categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects and toxicity management and then provide novel insights into challenges and future directions.
540 _aCreative Commons Attribution. See the linked licence for the applicable terms.
_uhttps://creativecommons.org/licenses/by/4.0/
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _ahematology
655 4 _aReview articles.
700 0 _aZhongpei Huang
_eauthor.
700 0 _aHeng Mei
_eauthor.
700 0 _aYu Hu
_eauthor.
773 0 _tSignal transduction and targeted therapy
_gVol. 8, no. 1, (2023), pages/article 306
_x2095-9907
856 4 0 _uhttps://europepmc.org/articles/PMC10435569
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC10435569
_qlocal
942 _n0
999 _c1182
_d1182